PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION
Abstract
The purpose of this study was to conduct the analysis of the structure and the rationality of cost in particular of providing preferential medicines patients with сhronic obstructive pulmonary disease (COPD) in Krasnoyarsk region.
Materials and methods. The database of Ministry of Health of Krasnoyarsk region and Territorial fund of obligatory medical insurance of Krasnoyarsk region on the released preferential preparations to patients with the code J44 on the territory of Krasnoyarsk region for 2014 was used. For the diagnosis of rationality costs method of pharmaco-economic analysis — АВС/VEN analysis — was applied.
Results. Most of the costs amounted to vital medicines (99.8%) of which the maximum share of costs associated with bronchodilators (73.9%) and a combination of DDBA and inhalation GCS (18.5%). In this research the most finances was spent on Tiotropium bromide (51%), Fenoterolum/Ipratropium bromide (18.7%) and Salmeterol/ Fluticasonum (11%). The nomenclature of International unlicensed name of the drugs which are released according to preferential prescriptions for 98.9% is bound to pathogenetic therapy of COPD and doesn't contradict to the modern recommendations on a pharmacotherapy of this pathology. Most of patients were provided with the following drugs of International unlicensed name: the combined preparation of Fenoterolum/ Ipratropium bromide (72.2%), a lond-acting cholinoblocker Tiotropium bromide (38.9%) and mucolytic preparation N- Acetylcysteinum (38.7%). To the category N is referred only 3 drugs of International unlicensed name the necessary of which is in doubt.
Conclusion. The ABC/ VEN analysis showed rational use of financial means on pharmacotherapy patients with COPD in Krasnoyarsk region. The list of drugs of International unlicensed name is consistent with the current recommendations for management of such patients.
About the Authors
T. V. Gaygolnik
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
post-graduate student, department of Internal Diseases N 2.,
ul. Partizana Zheleznyaka, 1, Krasnoyarsk, 660022
I. V. Demko
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
MD, professor & head, department of Internal Diseases N 2,
ul. Partizana Zheleznyaka, 1, Krasnoyarsk, 660022
E. N. Bochanova
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
PhD, associate professor, department of pharmacology with course of clinical pharmacology, pharmaceutical technology and course of post-graduate education,
ul. Partizana Zheleznyaka, 1, Krasnoyarsk, 660022
A. Yu. Kraposhina
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
PhD, assistant of the department of Internal Diseases N 2,
ul. Partizana Zheleznyaka, 1, Krasnoyarsk, 660022
N. V. Gordeeva
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
PhD, assistant of the department of Internal Diseases N 2,
ul. Partizana Zheleznyaka, 1, Krasnoyarsk, 660022
I. A. Soloveva
Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky
Russian Federation
Russian Federation
PhD, assistant, department of Internal Diseases N 2,
ul. Partizana Zheleznyaka, 1, Krasnoyarsk, 660022
References
1. Vorob'ev P. A. Clinical economic analysis [Klinikoekonomicheskii analiz (in Russian)]. Moscow. 2008; 778 s.
2. Gajgol'nik T. V., D emko I. V., Bochanova E. N., Gordeeva N. V., Kraposhina A. Ju., Solov'eva I. A. Pul'monologija. 2015, 3: 320-326.
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2014. URL: http://www.goldcopd.org/uploads/users/files/GOLD_2014.pdf. Accessed: 20.11.2015.
4. Report of World Health Organization. Chronic Obstructive Pulmonary Disease (COPD): Informacionnyj bjulleten' №315, — 2015g. URL: http://www.who.int/mediacentre/factsheets/fs315/ru/. Accessed: 20.11.2015.
5. Kozlov R. S., Krechikova O. I., Sivaja O. V., Krechikova O. I., Gudkov I. V.; Strachunskij L. S., Agapova E. D., Rozanova S. M., Furletova N. M., Gudkova L. V., Gugucidze E. N., Egorova R. R., Il'ina V. N., Katosova L. K., Manerov F. K., Marusina N. E., Multyh I. G., Nehaeva G. I., Nurtdinova N. M., Paljutin Sh. H., Smirnov I. V., Shhetinin E. V., Shturmina S. M., Ceneva G. Ja., Dzjublik A. Ja., Simonov S. S., Perceva T. A. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2002, 3(4): 267-277.
6. Krysanov I. S. Kachestvennaja klinicheskaja praktika. 2014; 2: 51-56.
7. Chuchalin A. G., Ajsanov Z. R., Avdeev S. N., Belevskij A. S., Leshhenko I. V., Meshherjakova N. N., Ovcharenko S. I., Shmelev E. I. Pul'monologija. 2014; 3: 15-36.
8. Artyukhov I. P., Arshukova I. L., Dobretsova E. A., Dugina T. A., Shulmin A. V., Demko I. V. Epidemiology of chronic obstructive pulmonary dis ease: a population-based study in Krasnoyarsk region, Russia. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 1781-1786.
9. Asche C. V., Leader S., Plauschinat C., Raparla S., Yan M., Ye X., Young D. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int. J. Chron. Obstruct Pulmon. Dis. 2015; 10 (1): 1093-1102.
10. Barr R. G., Bourbeau J., Camargo C. A., Ram F. S. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006; 61 (10): 854-862.
11. Bettoncelli G., Blasi F., Brusasco V., Centanni S., Corrado A., De Benedetto F., De Michele F., U Di Maria G., F Donner C., Falcone F., Mereu C., Nardini S., Pasqua F., Polverino M., Rossi A., Sanguinetti C. M. The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine). Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31 (1): 3-21.
12. Chuchalin A. G., Khaltaev N., Antonov N. S., Galkin D. V., Manakov L. G., Antonini P., Murphy M., Solodovnikov A. G., Bousquet J., Pereira M. H. S., Demko I. V. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 963-974.
13. Cosio М., Baraldo S., Saetta M. Inhaled Glucocorticoids and COPD Exacerbations. N Engl J Med. 2015; 372: 92-94.
14. Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 1093-1102.
15. Kew K. M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; 3: CD010115.
16. Magnussen H., Disse B., Rodriguez-Roisin R., Kirsten A., Watz H., Tetzlaff K., Towse L., Finnigan H., Dahl R., Decramer M., Chanez P., Wouters E. F., Calverley P. M. Investigators.et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371: 1285-1294.
17. Pascoe S., Locantore N., Dran sfield M., Barnes N. C., Pavord I. D. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3: 435-44 2.
18. Perera P. N., Armstrong E. P., Sherrill D. L., Skrepnek G. H. Acute Exacerbations of COPD in the United States: Inpatient Burden and Predictors of Costs and Mortality. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 9 (2): 131-141.
19. Poole P., Chong J., Cates C. J. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD001287. DOI: 10.1002/14651858.CD001287.pub5. URL: http://onlinelibrary.wiley.com/enhanced/doi/10.1002/14651858.CD001287.pub5 Accessed: 20.11.2015.
20. Skrepnek G. H., Skrepnek S. V. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am. J. Manag. Care. 2004; 10 (5): 129-138.
21. Tashkin D. P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
22. Tse H. N., Raiteri L., Wong K. Y., Yee K. S., Ng L. Y., Wai K. Y., Loo C. K., Chan M. H. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, pl acebo-controlled HIACE study. Chest. 2013; 144 (1): 106-118.
For citation:
Gaygolnik T.V., Demko I.V., Bochanova E.N., Kraposhina A.Y., Gordeeva N.V., Soloveva I.A. PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016;9(2):49-59. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.2.049-059
Views: 267
Email this article 